Top Markets
Coin of the day
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
株式のランク #20716
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel... MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.
株価
$0.00001
時価総額
$50.01K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 MultiCell Technologies, Inc. (MCET)

カテゴリー

MultiCell Technologies, Inc.(MCET)のP/B比率
March 2026 時点のP/B比率 TTM: -0.31
MultiCell Technologies, Inc. の最新の財務報告および株価によると、現在のP/B比率(TTM)は -0.31 です。2013 年末時点でのP/B比率は -3.89 でした。
MultiCell Technologies, Inc. の P/B 比率の履歴(2013 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
2026 (TTM) -0.31 -97.50%
2014 -12.57 223.02%
2013 -3.89 0.00%
同業他社のP/B比率
企業 P/B比率 P/B比率の差
5.6573 -1,899.97%
DK
6.3842 -2,131.24%
US
2.4551 -881.13%
US
4.364 -1,488.48%
BE
2.5504 -911.45%
AU